Last edition
News about "IRAKLIA trial"
US FDA Approves Subcutaneous Sarclisa for Multiple Myeloma Across All Existing Indications
Sanofi’s SC formulation becomes the first oncology therapy approved for administration via both an on-body injector and manual subcutaneous injection, offering shorter treatment times for patients.
IRAKLIA Trial | 13/07/2026 | By News Bureau
EU Approves Sanofi's Sarclisa SC as First On-Body Injector Cancer Therapy
Sanofi’s Sarclisa subcutaneous has received EU approval as the first anticancer therapy delivered via an On-Body Injector (OBI). Administered through the CirCLIQ OBI, the treatment offers flexible home or outpatient use for multiple myeloma patients while maintaining efficacy across all approved Sarclisa indications and combinations.
IRAKLIA Trial | 09/06/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy